<DOC>
	<DOCNO>NCT01633060</DOCNO>
	<brief_summary>This study evaluate whether addition daily BKM120 fulvestrant effective safe treat patient HR+ , HER2- , AI treat locally advanced metastatic breast cancer progress mTor inhibitor base treatment .</brief_summary>
	<brief_title>A Phase III Study BKM120 With Fulvestrant Patients With HR+ , HER2- , AI Treated , Locally Advanced Metastatic Breast Cancer Who Progressed After mTORi</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal woman Breast cancer locally advance metastatic HER2 negative disease , know positive hormone receptor status ( common breast cancer classification test ) A tumor sample must ship central lab identification biomarkers ( PI3K activation status ) randomization Prior treatment AIs Evidence progression combination mTORi endocrine therapy give last therapy prior study entry Adequate bone marrow organ function More 1 prior chemotherapy give locally advanced metastatic disease Previous treatment PI3K inhibitor , AKT inhibitor fulvestrant Symptomatic CNS metastasis Concurrent malignancy malignancy within 3 year prior start study treatment Certain drug radiation within 24 week enrollment Increasing chronic treatment ( &gt; 5 day ) corticosteroids another immunosuppressive agent Active heart ( cardiac ) disease history cardiac dysfunction define protocol Hyper sensitivity fulvestrant treatment excipients Certain score anxiety depression mood questionnaire give screen Acute viral hepatitis history chronic acute HBV , HCV , HAV , HDV , HEV Other protocol define criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BKM120</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>breast cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>AI treat</keyword>
	<keyword>mTOR inhibitor</keyword>
	<keyword>PI3K</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>PTEN</keyword>
	<keyword>HER2-</keyword>
	<keyword>HR+</keyword>
</DOC>